113 related articles for article (PubMed ID: 1515424)
1. Enhancement of lymphokine-activated killer activity induction in vitro by interleukin-1 administered in patients with urological malignancies.
Marumo K; Tachibana M; Deguchi N; Tazaki H
J Immunother (1991); 1992 Apr; 11(3):191-7. PubMed ID: 1515424
[TBL] [Abstract][Full Text] [Related]
2. [Effects of recombinant interleukin 1 beta on peripheral blood cells and induction of lymphokine-activated killer activity in patients with urological malignancies].
Marumo K; Ueno M; Muraki J; Tachibana M; Deguchi N; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1991 Aug; 82(8):1211-7. PubMed ID: 1921014
[TBL] [Abstract][Full Text] [Related]
3. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.
Klingemann HG; Wong E
Cancer Immunol Immunother; 1991; 33(6):395-7. PubMed ID: 1715237
[TBL] [Abstract][Full Text] [Related]
6. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
7. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
Heaton KM; Ju G; Grimm EA
Ann Surg Oncol; 1994 May; 1(3):198-203. PubMed ID: 7842289
[TBL] [Abstract][Full Text] [Related]
9. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
10. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
11. IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity.
Ebina N; Gallardo D; Shau H; Golub SH
Br J Cancer; 1990 Oct; 62(4):619-23. PubMed ID: 1699593
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
13. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
14. The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity.
Thompson JA; Lindgren CG; Benyunes MC; Bianco JA; Shields AF; Fefer A
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):84-90. PubMed ID: 8318500
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity.
Anderson PM; Ochoa AC; Ramsay NK; Hasz D; Weisdorf D
Blood; 1992 Oct; 80(7):1846-53. PubMed ID: 1391948
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma.
Kondo M; Nonomura N; Miki T; Kojima Y; Yokoyama M; Nakano E; Okuyama A
Oncology; 1998; 55(6):588-93. PubMed ID: 9778628
[TBL] [Abstract][Full Text] [Related]
17. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
18. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
19. The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2.
Carter CR; Hancock BW; Rees RC
Cancer Immunol Immunother; 1992; 35(4):264-70. PubMed ID: 1511461
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.
Nicolet CM; Surfus JM; Hank JA; Sondel PM
Cancer Immunol Immunother; 1998 Aug; 46(6):327-37. PubMed ID: 9756417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
